PharmaJet Archives - Page 2 of 4

Executive Moves

PharmaJet names Nathalie Landry as CSO

PharmaJet appointed Nathalie Landry as chief scientific officer to provide strategic leadership and ensure the company’s clinical and scientific programs align with its global commercial expansion. PharmaJet’s pipeline...

May 2, 2023

Developments

PharmaJet to present immune response DNA vaccine data

Closely-held PharmaJet will present results of a comprehensive review of published scientific literature comparing data associated with various DNA vaccine delivery methods at the World Vaccine Congress 2023 on April 5...

April 4, 2023

Developments

PharmaJet partner seeks EUA in India for needle-free Omicron booster

PharmaJet partner, Gennova Biopharmaceuticals, filed data for its mRNA-based Omicron specific COVID-19 booster shot for emergency use authorization (EUA) to the office of the Drug Controller General of India. The...

April 3, 2023

Developments

PharmaJet partner gets fast track for cancer vaccine

PharmaJet partner, Immunomic Therapeutics, received FDA fast track designation for a clinical study of its plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin...

December 13, 2022

Developments

PharmaJet receives NIH grant for HPV needle-free immunization study

Closely-held PharmaJet received an $800,000-plus direct to Phase 2 grant from the NIH to evaluate the immunogenicity of intradermal administration of human papilloma virus (HPV) vaccine using the company’s Tropis...

November 29, 2022

Developments

PharmaJet gets USAID contract to evaluate needle-free delivery in polio shots

Closely-held PharmaJet received a multi-year, $1.5-million grant from the United States Agency for International Development (USAID) to evaluate the impact of intradermal vaccine administration using the company’s...

October 24, 2022

Developments

PharmaJet partner, Scancell, to use needle-free delivery with melanoma vaccine

PharmaJet partner, Scancell, will include PharmaJet’s needle-free delivery system in a Phase 2 clinical study of a vaccine for treatment of patients with advanced melanoma. Scancell’s immunotherapy platform uses the...

August 2, 2022

Developments

PharmaJet sponsor study published in The Lancet

A Phase 3 clinical study sponsored by PharmaJet’s partner, Zydus Lifesciences, featuring ZyCoV-D, the world’s first plasmid-DNA vaccine approved for use in humans and delivered by the PharmaJet Tropis Intradermal needle...

June 8, 2022

Developments

PharmaJet presents partner data on immunogenicity with needle-free systems

Closely-held PharmaJet presented new research at the World Vaccine Congress about clinical studies across multiple vaccine and therapeutic development programs that have incorporated its needle-free delivery systems...

April 27, 2022

Developments

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Immunomic Therapeutics plans to start a Phase 1 clinical study of a plasmid DNA vaccine, ITI-3000, in patients with Merkel cell carcinoma (MCC), a rare but aggressive form of skin cancer, using PharmaJet’s...

March 15, 2022

Tag - PharmaJet

PharmaJet names Nathalie Landry as CSO

PharmaJet to present immune response DNA vaccine data

PharmaJet partner seeks EUA in India for needle-free Omicron booster

PharmaJet partner gets fast track for cancer vaccine

PharmaJet receives NIH grant for HPV needle-free immunization study

PharmaJet gets USAID contract to evaluate needle-free delivery in polio shots

PharmaJet partner, Scancell, to use needle-free delivery with melanoma vaccine

PharmaJet sponsor study published in The Lancet

PharmaJet presents partner data on immunogenicity with needle-free systems

Immunomic Therapeutics to use PharmaJet system in skin cancer trial

Subscribe